(Q38247457)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204227%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

review article

1 reference

title

Natural product and natural product derived drugs in clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204227%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204227%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Matthew A. Cooper

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204227%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Mark S Butler

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204227%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

1 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204227%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

published in

Natural Product Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204227%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204227%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204227%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

1612-1661

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204227%20AND%20SRC:MED&resulttype=core&format=json

Clinical development success rates for investigational drugs

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Decline in new drug launches: myth or reality? Retrospective observational study using 30 years of data from the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Financial aspects and the future of the pharmaceutical industry in the United States of america

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The role of natural product chemistry in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The evolving role of natural products in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Natural products and Pharma 2011: strategic changes spur new opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Natural products: a continuing source of novel drug leads

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Industrial natural product chemistry for drug discovery and development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Natural products as sources of new drugs over the 30 years from 1981 to 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Natural products to drugs: natural product derived compounds in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Natural products to drugs: natural product-derived compounds in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Expanding medicinal chemistry space

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Drug discovery beyond the 'rule-of-five'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The impact of natural products upon modern drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Natural products in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Natural products as sources of new drugs over the period 1981-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Natural products as sources of new drugs over the last 25 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Vitamin D, disease and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Functions, therapeutic applications, and synthesis of retinoids and carotenoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Recent developments of 2-substituted analogs of 1,25(OH)(2)D(3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Coenzyme Q10 as a therapy for mitochondrial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The role of vitamin D in reducing cancer risk and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Polymer-drug conjugates: present state of play and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The year's new drugs & biologics - 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The Year's New Drugs & Biologics - 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The year's new drugs & biologics, 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The year's new drugs & biologics, 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The year's new drugs & biologics, 2013: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

21 January 2018

2013 FDA drug approvals

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A study of the bacterial community in the root system of the maytansine containing plant Putterlickia verrucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

(-)-Cytisine and derivatives: synthesis, reactivity, and applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Cytisine: a natural product lead for the development of drugs acting at nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Efficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Targeting mTOR pathways in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Methylnaltrexone for the treatment of opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Opioid modulators for alcohol dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Stress Degradation Studies of Tebipenem and a Validated Stability-Indicating LC Method

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Crystal Structures of Biapenem and Tebipenem Complexed with Penicillin-Binding Proteins 2X and 1A from Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Semi-synthetic glycopeptide antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Romidepsin: a novel histone deacetylase inhibitor for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

VincaAlkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Vinflunine: review of a new vinca alkaloid and its potential role in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Essential structure of the κ opioid receptor agonist nalfurafine for binding to the κ receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Tubulin-targeted agents including docetaxel and cabazitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Cabazitaxel: a novel drug for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Molecular targets of FTY720 (fingolimod).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Stability and stabilization studies of TAK-599 (Ceftaroline Fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Macrocyclic ketone analogues of halichondrin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

From micrograms to grams: scale-up synthesis of eribulin mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Osteosarcoma treatment - where do we stand? A state of the art review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Transient receptor potential vanilloid 1 as a therapeutic target in analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

From natural product to marketed drug: the tiacumicin odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Natural products as insecticides: the biology, biochemistry and quantitative structure-activity relationships of spinosyns and spinosoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Natural products as sources for new pesticides

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Ingenol mebutate gel for actinic keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Proceedings of the First International Conference on PEP005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Euphorbia peplus: 18th-century insights on a 21st-century therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Epoxomicin, a new antitumor agent of microbial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Identification of an antimalarial synthetic trioxolane drug development candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Characterization of sirolimus metabolites in pediatric solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Recent developments in the maytansinoid antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Polyphenon E: a new treatment for external anogenital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The use of sinecatechins (polyphenon E) ointment for treatment of external genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antibiotics in the clinical pipeline in 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Investigational antimicrobial agents of 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Pipeline of Known Chemical Classes of Antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antibiotics in phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Origin, structure, and activity in vitro and in vivo of dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Synthesis and spectrum of the neoglycoside ACHN-490

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Combating evolution with intelligent design: the neoglycoside ACHN-490.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Mechanism of action of the novel aminomethylcycline antibiotic omadacycline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of LFF571: an investigational agent for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Chloramines as intermediates of oxidation reaction of amino acids by myeloperoxidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

13C-NMR study of taurine and chlorotaurine in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Quaternary ammonium N,N-dichloroamines as topical, antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

N-chloramines, a promising class of well-tolerated topical anti-infectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Efficacy of NVC-422 in the treatment of dermatophytosis caused by Trichophyton mentagrophytes using a guinea pig model

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

N-chlorotaurine, a long-lived oxidant produced by human leukocytes, inactivates Shiga toxin of enterohemorrhagic Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The synthetic amphipathic peptidomimetic LTX109 is a potent fungicide that disturbs plasma membrane integrity in a sphingolipid dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Efficient antibacterial agents: a review of the synthesis, biological evaluation and mechanism of pleuromutilin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Photodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Organization of the biosynthetic genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by Actinoplanes liguriae NCIMB41362.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

New horizons for host defense peptides and lantibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Sulfazecin and isosulfazecin, novel beta-lactam antibiotics of bacterial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

An insight into the antifungal pipeline: selected new molecules and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

New lead structures in antifungal drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

New β-glucan inhibitors as antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Novel antifungal agents: a patent review (2011 - present).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

From natural products to clinically useful antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Fluoride enhances the activity of fungicides that destabilize cell membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Crystal and molecular structure of an iodo-derivative of the cyclic undecapeptide cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Cyclophilin inhibitors as antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Update on alisporivir in treatment of viral hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Ion mobility spectrometry reveals the mechanism of amyloid formation of Aβ(25-35) and its modulation by inhibitors at the molecular level: epigallocatechin gallate and scyllo-inositol

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Comparison of three amyloid assembly inhibitors: the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Isolation and structure of a hoplonemertine toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Trial watch: opioid receptor blocker shows promise in Phase II depression trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Tetrodotoxin for Moderate to Severe Cancer Pain: A Randomized, Double Blind, Parallel Design Multicenter Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Tetrodotoxin (TTX) as a therapeutic agent for pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The molecular mystique of tetrodotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antineuropathic effects of the antibiotic derivative spicamycin KRN5500.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

SGLT inhibitors in management of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Canagliflozin: a new class of antidiabetic agent targeting the sodium-glucose cotransporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Pyridorin in type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Absolute configuration of beer's bitter compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

New and emerging drug molecules against obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Structure of human methionine aminopeptidase-2 complexed with fumagillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Pharmacological chaperone therapy for Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Structure and synthesis of nojirimycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Deoxynojirimycin: synthesis and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Polyhydroxylated alkaloids isolated from mulberry trees (Morusalba L.) and silkworms (Bombyx mori L.).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Accumulation of 1-deoxynojirimycin in silkworm, Bombyx mori L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats: the role of Na+K+-ATPase/ cSRC pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

OASIS-HT: design of a pharmacogenomic dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The discovery of dicumarol and its sequels

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Structural and functional insights into human vitamin K epoxide reductase and vitamin K epoxide reductase-like1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vivo and in vitro effects of SAR 943, a rapamycin analogue, on airway inflammation and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Chemical modification of rapamycin: the discovery of SDZ RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Curcumin as "Curecumin": from kitchen to clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Therapeutic roles of curcumin: lessons learned from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Structural basis for the cyclophilin A binding affinity and immunosuppressive potency ofE-ISA247 (voclosporin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

DA6034 promotes gastric epithelial cell migration and wound-healing through the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Second generation S1P pathway modulators: research strategies and clinical developments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

PKCθ: a new target for selective immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antibiotics in microbial ecology : Isolation and structure assignment of several new antibacterial compounds from the insect-symbiotic bacteriaXenorhabdus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A phase II trial of oral gimatecan for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Crystalline camptothecin-20(S)-O-propionate hydrate: a novel anticancer agent with strong activity against 19 human tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Curcumin in various cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Pan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Soy isoflavones and prostate cancer: a review of molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Syntheses and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Resveratrol in the management of human cancer: how strong is the clinical evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Resveratrol: from basic studies to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Minnelide: a novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

EC145: a novel targeted agent for adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmaco

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Anti-myeloma effects of the novel anthracycline derivative INNO-206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Isolation and first total synthesis of PM050489 and PM060184, two new marine anticancer compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Psammaplins from the Sponge Pseudoceratina purpurea: Inhibition of Both Histone Deacetylase and DNA Methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Panobinostat in lymphoid and myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Isolation and structure of bryostatin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Marine natural products: bryostatins in preclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antibody-drug conjugates in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Maturing antibody-drug conjugate pipeline hits 30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antibody-drug conjugates for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antibody-drug conjugates: an emerging concept in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Antibodies to watch in 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Zur Kenntnis des Curcumins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

The structure of tetrodotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Bryostatins: biological context and biotechnological prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Bacterial biosynthesis and maturation of the didemnin anti-cancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Comparative Antimalarial Activities and ADME Profiles of Ozonides (1,2,4-trioxolanes) OZ277, OZ439, and Their 1,2-Dioxolane, 1,2,4-Trioxane, and 1,2,4,5-Tetraoxane Isosteres

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Actinonin: an Antibiotic Substance produced by an Actinomycete

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Structure and Synthesis of Distamycin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4NP00064A

Halichondrins - antitumor polyether macrolides from a marine sponge

21 January 2018

1 reference

20 August 2023

https://opencitations.net/index/coci/api/v1/citations/10.1351/PAC198658050701

Epothilone A and B—Novel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution

1 reference

9 March 2024

https://opencitations.net/index/api/v1/citations/10.1002/ANIE.199615671

Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.53.879

Pneumocandins from Zalerion arboricola. I. Discovery and isolation

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.45.1853

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.47.301

Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.47.208

Generation of novel rapamycin structures by microbial manipulations

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.48.657

FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.41.1592

Studies on the differentiation inducers of myeloid leukemic cells. III. Spicamycin, a new inducer of differentiation of HL-60 human promyelocytic leukemia cells

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.36.934

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.727

Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.40.575

Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, bilogical and biochemical characterization.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.253

Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. I. Production, isolation, and physico-chemical and biological properties

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.39.1407

K-252a, a potent inhibitor of protein kinase C from microbial origin

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.39.1059

Identifiers

DOI

10.1039/C4NP00064A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204227%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference